As­traZeneca touts PhI­II event-free sur­vival win with Imfinzi

On the heels of Mer­ck re­port­ing a Phase III win with Keytru­da be­fore and af­ter surgery in non-small cell lung can­cer (NSCLC), As­traZeneca is an­nounc­ing its own win in the space — fol­low­ing a win from last sum­mer.

The UK phar­ma said Thurs­day that its an­ti-PD-1 drug Imfinzi, showed a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in event-free sur­vival when com­bined with neoad­ju­vant chemother­a­py be­fore surgery and af­ter surgery by it­self in an ad­ju­vant set­ting. The da­ta came from a planned in­ter­im analy­sis, As­traZeneca said, but no hard fig­ures were re­leased.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER